Syed Imran S, Sanborn Timothy A, Rosengart Todd K
Evanston Northwestern Healthcare, Evanston, IL, USA.
Cardiology. 2004;101(1-3):131-43. doi: 10.1159/000075994.
The use of angiogenic factors to effect therapeutic angiogenesis may be an attractive treatment modality for a substantial number of patients who have diffuse coronary artery disease and who are not candidates for traditional revascularization procedures. Delivery of angiogenic factors as a protein or gene encoding for the respective protein product has been shown to induce angiogenesis in numerous animal models, and expression of a functioning product has been demonstrated. Various early clinical trials of therapeutic angiogenesis have shown reduction in anginal symptoms and increases in exercise time, as well as objective evidence of improved perfusion, left ventricular function and angiographic appearance following such angiogenic treatments.
对于大量患有弥漫性冠状动脉疾病且不适合传统血运重建手术的患者而言,使用血管生成因子来实现治疗性血管生成可能是一种颇具吸引力的治疗方式。在众多动物模型中,已证实将血管生成因子作为蛋白质或编码相应蛋白质产物的基因进行递送可诱导血管生成,并且已证明有功能性产物的表达。治疗性血管生成的各种早期临床试验显示,心绞痛症状减轻、运动时间增加,以及有客观证据表明在进行此类血管生成治疗后灌注改善、左心室功能和血管造影表现得到改善。